T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis

Immune responses in people with multiple sclerosis (pwMS) receiving disease-modifying therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-targeting immunotherapies, including anti-CD20 treatments and sphingosine-1-phosphate receptor (S1PR) modulators, atte...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Asia-Sophia, Ravussin, Anthony, König, Marton, Øverås, Mathias H., Solum, Guri, Kjønstad, Ingrid Fadum, Chopra, Adity, Holmøy, Trygve, Harbo, Hanne F., Syversen, Silje Watterdal, Jørgensen, Kristin Kaasen, Høgestøl, Einar August, Vaage, Jon Torgils, Celius, Elisabeth G., Lund-Johansen, Fridtjof, Munthe, Ludvig A., Nygaard, Gro Owren, Mjaaland, Siri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371236/
https://www.ncbi.nlm.nih.gov/pubmed/37159281
http://dx.doi.org/10.1172/jci.insight.165111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371236/
https://www.ncbi.nlm.nih.gov/pubmed/37159281
http://dx.doi.org/10.1172/jci.insight.165111

Ejemplares similares